Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2014

View Archived Issues

Ebola virus evades the STAT1-mediated immune response

Novel EZH2 inhibitors for diffuse large B-cell lymphoma identified at Pfizer

Isis Pharmaceuticals designs new huntingtin ASOs

Novartis divulges new anti-IL-17A MAbs

German researchers disclose new MAGE A1-recognizing constructs

Discovery of antibacterial compounds with promising activity against Gram-positive pathogens

Novel LXR agonists for the treatment of lipoprotein disorders

INSERM reports new polypeptides for mitochondrial disorders

Swedish group patents new deuterated catecholamine derivatives

DMC recommends initiation of Ruthigen's phase I/II study of RUT-58-60

Patrys plans phase Ib/II study of PAT-SM6 with carfilzomib in multiple myeloma

Pfizer and Merck & Co. to evaluate combination of pembrolizumab and crizotinib

Alkermes initiates phase I trial of the opioid modulator ALKS-7106

NIH supports Sorrento Therapeutics' development of immunotherapy for IPF

BeiGene moves BTK inhibitor BGB-3111 into the clinic

FDA approves Promacta for severe aplastic anemia

Identification of TLR agonists as novel markers for SSc

Innate Pharma's IPH-4102 receives E.U. orphan drug status for cutaneous T-cell lymphoma

EMA accepts for review Cubist's MAA for ceftolozane/tazobactam

Vivolux plans phase I study of VLX-600 for refractory advanced solid tumors

Empagliflozin launched in the U.S. for type 2 diabetes

Adocia launches phase III study of BioChaperone PDGF-BB in diabetic foot ulcers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...